Latest Bone tumor Stories
A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens.
SAN MARINO, Calif., Oct. 12 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic.
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults.
A new analysis suggests patients and physicians should rethink the pros and cons of limb-sparing surgery versus amputation for bone and soft tissue sarcomas of the lower limb.
Limb-sparing surgery, which has been taking the place of amputation for bone and soft tissue sarcomas of the lower limb in recent years, may not provide much or even any additional benefit to patients according to a new review. The analysis, published in the September 15, 2009 issue of Cancer
HUNTSVILLE, Ala., May 5 /PRNewswire/ -- Osteosarcoma is the most common and potentially most dangerous bone cancer. It primarily affects young people between the ages of 10 - 25. In "Cancer from A to Z" (published by AuthorHouse), a new cancer dictionary by Dr.
Multiple, anatomically distinct lung cancer tumors may frequently arise from a single cancer cell, according to a retrospective analysis of patient tumor samples published in the April 7 online issue of the Journal of the National Cancer Institute.
First New Agent Approved to Treat Osteosarcoma in More Than 20 Years IRVINE, Calif., March 9 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
EUSAPharma (formerly Cytogen) Posts Positive Phase I Report from Trial of Quadramet in Combination with Velcade for the Treatment of Relapsed or Refractory Multiple Myeloma. LOS ANGELES, Feb.
- To swell, as grain or wood with water.